Last reviewed · How we verify
NCT07174739
Efficacy of Quantum Molecular Resonance in Neuropathic Corneal Pain and Corneal Nerve Regeneration
NA trial testing Quantum Molecular Resonance (QMR) Treatment in Neuropathic Corneal Pain in 30 participants. Currently enrolling.
31 October 2026
Quick facts
| Lead sponsor | Singapore Eye Research Institute |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 November 2023 |
| Primary completion | 31 October 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across Singapore |
Drugs / interventions tested
- Quantum Molecular Resonance (QMR) Treatment
Conditions studied
- Neuropathic Corneal Pain — all drugs for Neuropathic Corneal Pain →
Sponsor
Singapore Eye Research Institute
Who can join
21 and older, any sex, with Neuropathic Corneal Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to evaluate whether Quantum Molecular Resonance (QMR) treatment can effectively reduce eye pain and stimulate corneal nerve regeneration in patients with neuropathic corneal pain (NCP). Participants diagnosed with NCP will attend a total of nine study visits, consisting of one baseline assessment and eight QMR treatment sessions. At each visit, participants will undergo a series of clinical examinations to evaluate changes in the ocular surface, corneal nerves, and tear proteins, and will complete questionnaires regarding their symptoms, eye pain, and quality of life. The investigators will compare these outcomes before and after QMR treatment to determine whether QMR treatment alleviates NCP symptoms and enhances ocular surface and corneal nerve health. The investigators hypothesize that QMR treatment will provide notable pain relief, promote corneal nerve regeneration, and improve overall quality of life for NCP patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07174739
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Singapore Eye Research Institute trials
Trials by the same sponsor.
- NCT06983652 — Validation of the Use of Terahertz Scanning System on Corneal Scars and Corneal Edema · recruiting
- NCT06877988 — Artificial Intelligence (AI) - Assisted Visual Impairment Screening Model: Community-based Implementation and Evaluation · NA · active not recruiting
- NCT06967792 — Evaluation of the Safety of Terahertz Scanning System on Corneas · recruiting
- NCT06774651 — Comparison of Femto LDV Z8 Corneal Lenticule Extraction for Advanced Refractive Correction (CLEAR) and Visumax Small Inc · recruiting
- NCT05809674 — Polarization Sensitive Optical Coherence Tomography · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07174739 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Singapore Eye Research Institute
- Last refreshed: 19 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07174739.